PW Medtech’s Buying Spree: Diversification or Insider Story?

The manufacturer of medical infusion devices has recently made two interesting acquisitions Key takeaways: After buying a related peer in November, PW Medtech acquired a human tissue regeneration and repair product developer last week at a high premium The company’s performance has been affected by the pandemic, and it may hope the new acquisitions will lower such risk through diversification By Jony Ho Medical device maker PW Medtech Group Ltd. (1358.HK) has struggled lately, dragged down by pandemic-related disruptions. Perhaps seeking to lower that risk, the company has made two…

Read More »

FAST NEWS: Ascletis Pharma’s Cancer Drug Eyes U.S. with New Drug Application

The latest: Ascletis Pharma Inc. (1672.HK) announced it has filed an Investigational New Drug (IND) application in the U.S. for its self-house developed oral PD-L1 small molecule inhibitor, ASC61, for the treatment of advanced solid cancer tumors. Looking up: Before a new drug can be used in human clinical trials, the developer must submit an IND to the U.S. Food and Drug Administration (FDA) to ensure the safety and potential efficacy of the clinical test. If the IND is approved, the new drug will be granted a legal waiver to conduct…

Read More »

Coming Soon to Your Nearby Nayuki: Pricier Premium Tea Served by Robots

Beverage chain is squarely focused on higher end of competitive market, with 45% of its stores now labeled with its upmarket Nayuki PRO sub-brand Key Takeaways: Nayuki accelerated its aggressive expansion in the fourth quarter, with a sharp focus on its higher-end PRO-branded premium tea stores Company trialed automated tea-making machines at end of last year’s fourth quarter, and plans broader rollout in this year’s third quarter By Doug Young Who needs people? That’s one of the subtler messages in a new business update from premium tea chain Nayuki Holdings…

Read More »